Financial Performance - The company achieved operating revenue of RMB 66.226 billion in Q1 2023, representing a year-on-year growth of 16.39%[7] - The net profit attributable to shareholders was RMB 1.518 billion, reflecting a year-on-year growth of 21.31%[7] - The pharmaceutical commercial segment generated RMB 58.425 billion in sales, marking a year-on-year growth of 16.92%[7] - The sales of the innovative drug segment increased by approximately 28% year-on-year, with 7 new imported products introduced[13] - Net profit for Q1 2023 reached approximately ¥1.95 billion, up 27.5% from ¥1.53 billion in Q1 2022[27] - Total comprehensive income for Q1 2023 was approximately ¥1.92 billion, compared to ¥1.49 billion in Q1 2022, reflecting a growth of 28.7%[29] - Basic earnings per share for Q1 2023 were ¥0.41, a decrease from ¥0.44 in Q1 2022[29] - The company reported a basic earnings per share of ¥0.41, down by 6.75% year-on-year[14] Research and Development - R&D investment totaled RMB 547 million, an increase of 15.80% year-on-year, with R&D expenses at RMB 541 million, up 20.82%[7] - The company has 64 new drug candidates in clinical research, including 52 innovative drugs and 12 improved new drugs[9] - The first self-developed 1.1 class new drug, I001, has completed Phase III clinical trials for hypertension, achieving primary endpoint success[10] - The company submitted a pre-NDA application for I008-A, targeting chronic immune disorders related to HIV, aiming to fill clinical gaps[10] - R&D expenses increased to ¥540.69 million in Q1 2023, compared to ¥447.50 million in Q1 2022, indicating a focus on innovation[26] - Research and development expenses increased to ¥124,552,189.62 in Q1 2023 from ¥106,026,867.46 in Q1 2022, reflecting a growth of approximately 17.5%[36] Financial Position - The total assets at the end of the reporting period were ¥206,035,799,280.43, a 3.99% increase from the previous year[15] - The company's total assets reached ¥206.04 billion as of March 31, 2023, up from ¥198.13 billion at the end of 2022[25] - The equity attributable to shareholders increased to ¥68.57 billion as of March 31, 2023, from ¥67.06 billion at the end of 2022, reflecting growth in shareholder value[25] - Total liabilities increased to ¥126.15 billion as of March 31, 2023, compared to ¥120.13 billion at the end of 2022, indicating higher financial obligations[25] - The company's current assets totaled RMB 157,170,379,297.84 as of March 31, 2023, compared to RMB 149,512,870,619.79 as of December 31, 2022, reflecting an increase[22] Cash Flow - The net cash flow from operating activities was negative at -¥2,623,322,412.29, indicating a significant cash outflow[14] - Cash inflow from operating activities in Q1 2023 was approximately ¥64.27 billion, an increase from ¥55.91 billion in Q1 2022[30] - Cash outflow from operating activities totaled approximately ¥66.90 billion in Q1 2023, compared to ¥58.40 billion in Q1 2022[31] - The company reported cash inflow from investment activities of approximately ¥9.56 billion in Q1 2023, significantly higher than ¥180.58 million in Q1 2022[31] - Cash outflow from investment activities in Q1 2023 was approximately ¥11.67 billion, compared to ¥811.68 million in Q1 2022[31] - The total cash and cash equivalents at the end of Q1 2023 amounted to ¥24,104,731,465.82, down from ¥34,611,200,668.81 at the end of 2022, representing a decrease of 30.5%[32] Shareholder Information - The total number of common shareholders at the end of the reporting period was 78,061[20] - The top three shareholders held the following shares: Shanghai Pharmaceuticals Group (716,516,039 shares, 19.373%), HKSCC Nominees Limited (689,221,624 shares, 18.635%), and Yunnan Baiyao (665,626,796 shares, 17.997%)[19] - The total number of issued A-shares was 2,779,426,455 and H-shares was 919,072,704, totaling 3,698,499,159 shares[20] Market Expansion - The company is focusing on the traditional Chinese medicine sector, with plans to enhance the value of its eight core TCM enterprises[11] - The company plans to continue deepening its focus on the Southeast Asian market and expanding its global commercial footprint[13] - The company expanded its international presence by launching four specifications of Rosuvastatin Calcium Tablets in the Philippines[13] Investment Performance - The profit contribution from major equity investments was RMB 177 million, down 15.12% year-on-year[7] - The company reported a net investment income of ¥155.16 million in Q1 2023, down from ¥179.73 million in Q1 2022, indicating fluctuations in investment performance[26] - Investment income for Q1 2023 was reported at ¥225,801,358.48, compared to ¥192,498,159.54 in Q1 2022, showing an increase of approximately 17.3%[36]
上海医药(02607) - 2023 Q1 - 季度业绩